Altimmune Management
Management criteria checks 2/4
Altimmune's CEO is Vipin Garg, appointed in Nov 2018, has a tenure of 5.5 years. total yearly compensation is $5.48M, comprised of 11.3% salary and 88.7% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $2.10M. The average tenure of the management team and the board of directors is 3.6 years and 5.6 years respectively.
Key information
Vipin Garg
Chief executive officer
US$5.5m
Total compensation
| CEO salary percentage | 11.3% |
| CEO tenure | 5.5yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10
Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Altimmune: Changing The Thesis
Oct 16Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns
Sep 17We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely
Aug 06Altimmune: NASH And Obesity At The End Of The COVID Tunnel
Jul 27Altimmune rises 5% on positive ALT-801 data in early-stage trial of overweight volunteers
Jun 16Altimmune gains 7% after AdCOVID shows strong immune response against COVID-19 variant in preclinical study
May 26Altimmune reports encouraging AdCOVID data in SARS-CoV-2 challenged mice
May 10We Think Altimmune (NASDAQ:ALT) Can Easily Afford To Drive Business Growth
May 02Investors Who Bought Altimmune (NASDAQ:ALT) Shares A Year Ago Are Now Up 459%
Mar 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$5m | US$620k | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$78m |
| Jun 30 2023 | n/a | n/a | -US$81m |
| Mar 31 2023 | n/a | n/a | -US$85m |
| Dec 31 2022 | US$3m | US$580k | -US$85m |
| Sep 30 2022 | n/a | n/a | -US$87m |
| Jun 30 2022 | n/a | n/a | -US$97m |
| Mar 31 2022 | n/a | n/a | -US$102m |
| Dec 31 2021 | US$3m | US$566k | -US$97m |
| Sep 30 2021 | n/a | n/a | -US$84m |
| Jun 30 2021 | n/a | n/a | -US$68m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$1m | US$514k | -US$49m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$36m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$815k | US$500k | -US$21m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$34m |
| Mar 31 2019 | n/a | n/a | -US$40m |
| Dec 31 2018 | US$2m | US$44k | -US$42m |
Compensation vs Market: Vipin's total compensation ($USD5.48M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.
CEO
Vipin Garg (65 yo)
5.5yrs
Tenure
US$5,482,089
Compensation
Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.5yrs | US$5.48m | 0.41% $ 2.1m | |
| Chief Medical Officer | 4.8yrs | US$2.24m | 0.076% $ 385.6k | |
| Chief Business Officer | 1.3yrs | US$2.94m | 0.019% $ 98.8k | |
| Chief Financial Officer | 2.4yrs | US$619.69k | 0.063% $ 323.6k | |
| Chief Technology Officer | 7yrs | no data | no data | |
| Chief Scientific Officer | 11.4yrs | US$1.41m | 0.060% $ 306.8k | |
| Vice President of Quality & Compliance Management | 2.3yrs | no data | no data | |
| Corporate Controller | 1.3yrs | no data | no data |
3.6yrs
Average Tenure
65yo
Average Age
Experienced Management: ALT's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.5yrs | US$5.48m | 0.41% $ 2.1m | |
| Independent Chairman | 14.1yrs | US$119.68k | 0.037% $ 189.6k | |
| Independent Director | 19.8yrs | US$103.68k | 0.0039% $ 19.9k | |
| Independent Director | 7yrs | US$109.68k | 0.042% $ 214.1k | |
| Independent Director | 7yrs | US$115.68k | 0.037% $ 191.1k | |
| Independent Director | 7yrs | US$104.68k | 0.013% $ 66.0k | |
| Independent Director | 5.8yrs | US$108.68k | 0.012% $ 61.1k | |
| Independent Director | 4yrs | US$95.68k | 0% $ 0 | |
| Member of Mash Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Mash Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Mash Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Mash Scientific Advisory Board | 1.8yrs | no data | no data |
5.6yrs
Average Tenure
71yo
Average Age
Experienced Board: ALT's board of directors are considered experienced (5.6 years average tenure).